1. Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies

   • Milo Gatti
   • Fabrizio De Ponti
   • Federico Pea

   Review Article Open access 18 April 2021 Pages: 345 - 384

   

2. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis

   • Reshmi Roy
   • Alaa A. Alotaibi
   • Mark S. Freedman

   Review Article 02 April 2021 Pages: 385 - 402

3. Pharmacotherapy for Preschool Children with Attention Deficit Hyperactivity Disorder (ADHD): Current Status and Future Directions

   • Jonathan R. Young
   • Adare Yanagihara
   • Scott H. Kollins

   Review Article 26 March 2021 Pages: 403 - 424

4. Pharmacotherapy for Frontotemporal Dementia

   • Rita Khoury
   • Yu Liu
   • George T. Grossberg

   Review Article 11 April 2021 Pages: 425 - 438

5. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report

   • Emma Morton
   • Venkat Bhat
   • the CAN-BIND Investigator Team

   Original Research Article 16 April 2021 Pages: 439 - 450

6. The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study

   • Arnold P. M. van der Lee
   • Ibrahim Önsesveren
   • Niels C. L. Mulder

   Original Research Article Open access 10 April 2021 Pages: 451 - 460

   

7. Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program

   • Olivier Corbeil
   • Stéphanie Corbeil
   • Marc-André Roy

   Original Research Article 13 March 2021 Pages: 461 - 468